<![CDATA[Biomarker Testing and Treatment Selection in HR+/HER2− mBC]]>

Neutral

AI Analysis

Summary

Educational article discussing biomarker testing methods (liquid and tissue biopsies) for identifying ESR1 and PI3K mutations to guide second-line therapy selection in HR+/HER2− metastatic breast cancer.

Importance:2/10

Sentiment:

0.00

biomarker testingmetastatic breast cancerHR+/HER2−ESR1 mutationsPI3K mutationsliquid biopsytissue biopsytreatment selection

Read the original article

Published by Cancer Network on August 31, 2026 9:09 PM

Read Original